SALVATORE FOCELLA
Allopathic & Osteopathic Physicians|Internal Medicine PARAMUS, NJ NPI 1013901511
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine NJ Gilead Sciences, Inc. All categories
General Payments — all program years on this page
$3,327.61
- Category: General Payments
- Program years: PY2018–2024
- Record count: 56
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $737.58 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $737.58 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $249.96 | 2 |
| Acerta Pharma LLC | $138.45 | 2 |
| Janssen Pharmaceuticals, Inc | $127.88 | 1 |
| Teva Pharmaceuticals USA, Inc. | $110.84 | 1 |
| Alkermes, Inc. | $110.45 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078094226 | Janssen Pharmaceuticals, Inc | $127.88 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1104215693 | AstraZeneca Pharmaceuticals LP | $16.61 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1104525088 | AstraZeneca Pharmaceuticals LP | $121.84 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120499496 | Alkermes, Inc. | $110.45 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133751534 | Gilead Sciences, Inc. | $124.98 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133751536 | Gilead Sciences, Inc. | $124.98 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151696897 | Teva Pharmaceuticals USA, Inc. | $110.84 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.